Data from a EURODIAB randomized controlled trial lisinopril in IDDM [46] showed that the I/D polymorphism of the ACE gene modulates the therapeutic effect of ACE inhibition on the progression of urinary albumin excretion in IDDM patients. This evidence concerns the gene ALB and type 1 diabetes mellitus.